Početna › Autoimune bolesti › Massachusetts › Boston
Kliničke studije za Autoimune bolesti u gradu Boston, MA
13 studija za Autoimune bolesti traži sudionike na lokacijama u gradu Boston i okolici (unutar oko 30 milja). Otvorite studiju da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
U tijeku regrutacijaFaza 3
- Tufts Medical Center, Boston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
U tijeku regrutacijaFaza 1
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
U tijeku regrutacijaFaza 3
- Massachusetts General Hospital, Boston
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
U tijeku regrutacijaFaza 2/3
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
U tijeku regrutacijaFaza 3
- Massachusetts General Hospital, Boston
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
U tijeku regrutacijaFaza 1/2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Boston Children's Hospital, Boston
- i još 1
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
U tijeku regrutacijaFaza 1/2
- Beth Israel Deaconess Medical Center, Boston
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
U tijeku regrutacijaFaza 3
- Boston Children's Cancer Center, Boston
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
U tijeku regrutacijaFaza 1
- Brigham And Womens Hospital, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
U tijeku regrutacijaOpažajna studija
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
U tijeku regrutacijaFaza 1
- Tufts University, Boston
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
U tijeku regrutacijaFaza 1/2
- Brigham and Women's Hospital, Boston
Testimonials and Navigation in Rheumatology
U tijeku regrutacija
- Brigham Women's Hospital, Boston
Studije za Autoimune bolesti u drugim gradovima
- Houston, TX21 studija
- Washington, DC19 studija
- New York City, NY19 studija
- Philadelphia, PA16 studija
- Durham, NC15 studija
- Los Angeles, CA12 studija
- Chicago, IL12 studija
- Dallas, TX9 studija
- Cleveland, OH8 studija
- Milwaukee, WI8 studija
- Atlanta, GA8 studija
- Portland, OR8 studija
Ostale studije u gradu Boston
- Rak dojke111 studija
- Nemikrocelularni karcinom pluća90 studija
- Rak (sve vrste)86 studija
- Kolorektalni rak63 studija
- Metastatski karcinom63 studija
- Rak pluća62 studija
- Rak jajnika61 studija
- Rak prostate59 studija
- Depresija52 studija
- Rak endometrija50 studija
- Srčano zatajenje44 studija
- Akutna mijeloična leukemija44 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.